Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Holmes, Frankie Ann ^a   Espina, Virginia ^b   Liotta, Lance A ^b   Nagarwala, Yasir M ^c   Danso, Michael ^d   McIntyre, Kristi J ^e   Osborne, Cynthia R C ^f   Anderson, Thomas ^e   Krekow, Lea ^e   Blum, Joanne L ^f   Pippen, John ^f   Florance, Allison ^c   Mahoney, Janine ^c   O'Shaughnessy, Joyce A ^f  

^a MEMORIAL HERMANN HOSPITAL   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Virginia Oncology Associates   (United States)

^e TEXAS ONCOLOGY   (United States)

^f Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

Autophagy; Invasive breast cancer; Lapatinib; Protein signaling; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; LAPATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PHARMACOLOGICAL BIOMARKER; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; STAT5 PROTEIN; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AUTOPHAGY; BREAST TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PTEN PHOSPHOHYDROLASE; QUINAZOLINES; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84889017488     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-507     Document Type: Article

References (22)

1. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N, N Engl J Med 2005 353 1673 1684 10.1056/NEJMoa052122 16236738 (Pubitemid 41464706)
2. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE Jr, et al. J Clin Oncol 2011 29 3366 3373 10.1200/JCO.2011.35.0868 21768458
3. What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? von Minckwitz G, Loibl S, Untch M, Oncology 2012 26 20 26 22393792
4. Treatment of HER2-positive breast cancer: current status and future perspectives. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L, Nat Rev Clin Oncol 2012 9 16 32
5. The ERBB network: at last, cancer therapy meets systems biology. Yarden Y, Pines G, Nat Rev Cancer 2012 12 553 563 10.1038/nrc3309 22785351
6. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. Petricoin EF III, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA, J Clin Oncol 2005 23 3614 3621 10.1200/JCO.2005.02.509 15908672
7. Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute, http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
8. One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. Mueller C, Edmiston KH, Carpenter C, Gaffney E, Ryan C, Ward R, White S, Memeo L, Colarossi C, Petricoin EF 3rd, Liotta LA, Espina V, PLoS One 2011 6 23780 10.1371/journal.pone.0023780 21858221
9. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG, J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
10. NeoALTTO study team. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch M, Gelber RD, Piccart-Gebhart M, Lancet 2012 379 633 640 10.1016/S0140-6736(11)61847-3 22257673
11. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P, Lancet Oncol 2012 13 25 32 10.1016/S1470-2045(11)70336-9 22153890
12. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB) [abstract]. Guarneri V, Frassoldati A, Bottini A, Generali DG, Cagossi K, Artioli F, Bisagni G, Boni Ravaioli CA, Amadori D, Musolino A, Cavanna L, Untch M, Orlando L, Giardina G, Piacentini F, Tagliafico E, Bagnalasta M, D'Amico R, Conte PF, J Clin Oncol 2011 29 bstract 507
13. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF 3rd, Liotta LA, Mol Cell Proteomics 2008 7 1998 2018 10.1074/mcp.M700596-MCP200 18667411
14. FOXO1A is a target for HER2 overexpressing breast tumors. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV, Cancer Res 2010 70 5475 5485 10.1158/0008-5472.CAN-10-0176 20551062
15. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H, Oncogene 2005 24 746 760 10.1038/sj.onc.1208203 15592524 (Pubitemid 40216084)
16. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H, J Clin Oncol 2011 29 2448 2458 10.1200/JCO.2010.30.3552 21576635
17. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Gowda A, Roda J, Hussain SR, Ramanunni A, Joshi T, Schmidt S, Zhang X, Lehman A, Jarjoura D, Carson WE, Kindsvogel W, Cheney C, Caligiuri MA, Tridandapani S, Muthusamy N, Byrd JC, Blood 2008 111 4723 4730 10.1182/blood-2007-07-099531 18182577
18. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines. Cavazzoni A, Alfieri RR, Cretella D, Saccani F, Ampollini L, Galetti M, Quaini F, Graiani G, Madeddu D, Mozzoni P, Galvani E, La Monica S, Bonelli M, Fumarola C, Mutti A, Carbognani P, Tiseo M, Barocelli E, Petronini PG, Ardizzoni A, Mol Cancer 2012 11 91 105 10.1186/1476-4598-11-91 23234355
19. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA, PLoS One 2009 4 6251 10.1371/journal.pone.0006251 19606230
20. Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ, Cancer Res 2009 69 2191 2194 10.1158/0008-5472.CAN-08-1056 19276389
21. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S, J Clin Oncol 2012 30 1796 1804 10.1200/JCO.2011.38.8595 22508812
22. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL, Proc Natl Acad Sci USA 2006 103 7795 7800 10.1073/pnas.0602468103 16682622